Three Things You Should Know About the ESR1 Mutation in Breast Cancer

ESR1 mutations are not typically present at the time of an initial breast cancer diagnosis. They tend to develop later, most often after prolonged exposure to endocrine (hormone) therapies, such as aromatase inhibitors, that are designed to block estrogen signaling.

ESR1 is the gene that encodes the estrogen receptor. In ER-positive breast cancer, tumor growth is driven by estrogen binding to this receptor. Endocrine therapies work by either lowering estrogen levels in the body or blocking the receptor’s ability to respond to estrogen.

Over time, however, some cancer cells adapt. Under the pressure of treatment, they may acquire mutations in ESR1 that allow the estrogen receptor to remain “on” even when estrogen levels are very low. In practical terms, this means the cancer learns how to grow without needing estrogen in the usual way.

This is why ESR1 mutations are more commonly found in patients whose disease has progressed after multiple lines of hormone therapy, Dr. Kabraji explains. “ESR1 mutated breast cancer becomes more common the longer you’re on treatment,” he says.

For patients, this matters because disease progression on endocrine therapy could be a biological signal that the cancer has changed in a specific, testable way, and that different treatments may now be more effective.

2. ESR-1 Testing Can Be Done Through Blood Or Tumor Tissue

Historically, understanding tumor genetics often required a new tissue biopsy, which can be invasive, uncomfortable, or sometimes unsafe depending on where the cancer is located. But luckily, that’s not the case with ESR1 testing.

“Testing can happen either by tumor tissue or by blood, so even if tissue is not available, blood is a very accessible way of doing it,” Dr. Kabraji explains.

This blood-based test, commonly referred to as a liquid biopsy, looks for circulating tumor DNA (ctDNA), or tiny fragments of cancer DNA that are shed into the bloodstream.

Liquid biopsies also have another advantage: they can capture tumor changes in real time. Because ESR1 mutations often emerge during treatment, a blood test at the time of disease progression may be more informative than older tissue samples taken years earlier.

For patients, this means testing is not something to fear or delay. It is a practical, increasingly routine part of care for advanced ER-positive breast cancer, and it can directly inform what treatment comes next.

3. There Are FDA-Approved Treatments, And More Are Coming

Perhaps the most important reason ESR1 testing matters is that there are now Food and Drug Administration (FDA)-approved therapies specifically designed to treat ESR1-mutant breast cancer.

These newer therapies work differently from older endocrine treatments. Rather than simply lowering estrogen levels, they are designed to more directly degrade or block the altered estrogen receptor, including receptors that carry ESR1 mutations. This allows them to remain effective even when standard hormone therapies no longer work.

Dr. Kabraji highlights that this is a rapidly evolving area. Current FDA-approved options already give patients meaningful alternatives after progression on prior therapies, and ongoing clinical trials are testing additional drugs, both as single agents and in combination with other targeted treatments.

This shift has changed the stakes of testing. ESR1 status is now a decision-making tool. Knowing whether an ESR1 mutation is present can help oncologists choose treatments that are more likely to work now, rather than relying on therapies the cancer has already learned to resist.

For patients with advanced breast cancer, this means ESR1 testing should be viewed as part of the standard “care package,” especially at the time of progression. It opens doors to therapies that are specifically matched to how the cancer has evolved.

Why This Matters For Patients Right Now

The most important takeaway is that ESR1 mutations reflect change. They are a sign that the cancer has adapted, and that treatment needs to adapt as well.

Testing for ESR1 mutations allows patients and their doctors to make more precise decisions, avoid ineffective therapies, and take advantage of treatments designed for this exact situation.

As more targeted therapies become available, the value of knowing ESR1 status will only continue to grow.

Questions To Ask Your Doctor

• Have I been tested for an ESR1 mutation, and if not, should I be tested now?
• Can this testing be done with a blood test instead of a tissue biopsy?
• How would an ESR1 mutation change my treatment options?
• Are there FDA-approved therapies or clinical trials that specifically target ESR1-mutant breast cancer?

Learn more about SurvivorNet's rigorous medical review process.

---